ScripNovo Nordisk A/S has been spending huge sums to boost manufacturing capacity to meet demand for its GLP-1 drugs and the Danish major's latest megabucks investment is good news for workers in the US b
ScripEli Lilly and Company is committing an additional $5.3bn to its ongoing efforts to ramp up manufacturing of tirzepatide, the blockbuster dual GLP-1/GIP agonist approved as Mounjaro for type 2 diabete